AstraZeneca plc vs Google Inc — how do they compare? AstraZeneca plc trades at $158.58 (market cap $248.14B), while Google Inc trades at $341.63 (market cap $4.20T). The key difference: Google Inc is far larger — about 16.9× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | GOOG | |
|---|---|---|
Market Cap | $248.14B | $4.20T |
Sector | Health | Technology |
52-Week High | $209.48 | $399.06 |
52-Week Low | $147.06 | $200.19 |
Enterprise Value | $275.41B | $4.09T |
Dividend Yield | 2.01% | 0.26% |
Volume | — | 1,511,127 |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Alphabet (GOOG) trades at $340.22, down 4.39% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals, with revenue growing from $282.8B in 2022 to $402.84B in 2025 and net income margin expanding to 32.8%. Recent earnings beats and a consensus analyst price target of $431.67 suggest upside potential, though high capital expenditure plans and regulatory scrutiny pose risks.
The outlook remains positive due to robust AI adoption, with Gemini reaching 1 billion users, but investors face headwinds from elevated capex and antitrust investigations. Wall Street sentiment is overwhelmingly bullish, with 86.84% of analysts rating it a buy, highlighting growth prospects amid competitive and regulatory challenges.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →